# Quality Assurance Policy for diagnostic products

The Board approves the quality assurance policy for diagnostic products ("QA Policy for Diagnostics"), as set out in Annex 2 to the Report of the Market Dynamics and Commodities Ad-hoc Committee to the Board (GF/B22/11, Revision 1).

The Board requests the Secretariat to work with the World Health Organisation (WHO) towards concluding an agreement under which WHO will manage the technical evaluation of diagnostic products, including, as relevant, the establishment of an Expert Review Panel for Diagnostics, as described in the QA Policy for Diagnostics.

The Board further requests the Secretariat to work with WHO to explore measures to ensure principal recipients procure appropriately performing malaria rapid diagnostic tests (RDTs) and the MDC to report back by the Twenty-Fourth Board Meeting.